Science park launches cell & gene therapy accelerator to de-risk early stage research Advanced therapy expertise & up to €500,000 in funding for European researchers

June 29th 2021


Brussels South Charleroi BioPark (BSCB), the science-driven biopark at
the heart of Europe, has launched a Cell and Gene Therapy Accelerator program to de-risk early stage
research and create the advanced therapy companies of the future. With access to industry expertise and
scientific infrastructure plus up to €500,000 in funding per project, the Accelerator has been established to
de-risk research at the proof-of-concept stage. The financing comes from BSCB’s Butterfly Fund and regional
non-dilutive R&D grants from the Walloon Region. The program is co-chaired by Drs Miguel Forte (Bone
Therapeutics, ARM1 and ISCT²) and Christian Homsy (Capstan Therapeutics, ex Celyad).

Read Pdf